Porton Pharma Solutions Ltd. (300363.SZ)
CNY 17.08
(0.59%)
CNY 17.08
(0.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 242.94 Million CNY | 112.61% |
| 2022 | -1.92 Billion CNY | -304.68% |
| 2021 | -476.09 Million CNY | 43.95% |
| 2020 | -849.41 Million CNY | -2.67% |
| 2019 | -827.31 Million CNY | -145.18% |
| 2018 | -337.43 Million CNY | -151.8% |
| 2017 | 651.43 Million CNY | 12.11% |
| 2016 | 581.06 Million CNY | -13.29% |
| 2015 | 670.15 Million CNY | 276.42% |
| 2014 | 178.03 Million CNY | 30.35% |
| 2013 | 136.57 Million CNY | 131.91% |
| 2012 | 58.89 Million CNY | 129.02% |
| 2011 | 25.71 Million CNY | 17.99% |
| 2010 | 21.79 Million CNY | -42.44% |
| 2009 | 37.86 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 723.65 Million CNY | 86.63% |
| 2024 Q1 | 387.75 Million CNY | 59.61% |
| 2024 Q3 | -330.19 Million CNY | -63.75% |
| 2023 Q4 | 242.94 Million CNY | 130.92% |
| 2023 FY | 242.94 Million CNY | 112.61% |
| 2023 Q3 | -785.78 Million CNY | 31.76% |
| 2023 Q2 | -1.15 Billion CNY | 28.54% |
| 2023 Q1 | -1.61 Billion CNY | 16.37% |
| 2022 Q2 | -287.57 Million CNY | 47.15% |
| 2022 Q1 | -544.16 Million CNY | -14.3% |
| 2022 FY | -1.92 Billion CNY | -304.68% |
| 2022 Q4 | -1.92 Billion CNY | 11.31% |
| 2022 Q3 | -2.17 Billion CNY | -655.42% |
| 2021 Q3 | -745.71 Million CNY | 19.64% |
| 2021 Q1 | -622.61 Million CNY | 26.7% |
| 2021 FY | -476.09 Million CNY | 43.95% |
| 2021 Q4 | -476.09 Million CNY | 36.16% |
| 2021 Q2 | -928.01 Million CNY | -49.05% |
| 2020 Q2 | -787.15 Million CNY | 3.28% |
| 2020 FY | -849.41 Million CNY | -2.67% |
| 2020 Q4 | -849.41 Million CNY | 2.68% |
| 2020 Q3 | -872.81 Million CNY | -10.88% |
| 2020 Q1 | -813.83 Million CNY | 1.63% |
| 2019 Q1 | -112.52 Million CNY | 66.65% |
| 2019 Q3 | -717.47 Million CNY | -24.46% |
| 2019 FY | -827.31 Million CNY | -145.18% |
| 2019 Q4 | -827.31 Million CNY | -15.31% |
| 2019 Q2 | -576.48 Million CNY | -412.31% |
| 2018 Q4 | -337.43 Million CNY | 43.24% |
| 2018 Q3 | -594.47 Million CNY | -42.52% |
| 2018 Q2 | -417.11 Million CNY | -160.04% |
| 2018 Q1 | 694.71 Million CNY | 6.64% |
| 2018 FY | -337.43 Million CNY | -151.8% |
| 2017 Q2 | 624.92 Million CNY | 24.04% |
| 2017 Q1 | 503.79 Million CNY | -13.3% |
| 2017 FY | 651.43 Million CNY | 12.11% |
| 2017 Q4 | 651.43 Million CNY | -10.36% |
| 2017 Q3 | 726.74 Million CNY | 16.29% |
| 2016 Q1 | 681.55 Million CNY | 1.7% |
| 2016 Q2 | 654.1 Million CNY | -4.03% |
| 2016 Q3 | 627.63 Million CNY | -4.05% |
| 2016 FY | 581.06 Million CNY | -13.29% |
| 2016 Q4 | 581.06 Million CNY | -7.42% |
| 2015 FY | 670.15 Million CNY | 276.42% |
| 2015 Q4 | 670.15 Million CNY | 20.58% |
| 2015 Q3 | 555.79 Million CNY | 42.04% |
| 2015 Q2 | 391.28 Million CNY | 60.45% |
| 2015 Q1 | 243.86 Million CNY | 36.98% |
| 2014 Q4 | 178.03 Million CNY | -22.13% |
| 2014 Q3 | 228.63 Million CNY | 170.59% |
| 2014 FY | 178.03 Million CNY | 30.35% |
| 2014 Q2 | 84.49 Million CNY | 480.5% |
| 2014 Q1 | -22.2 Million CNY | -116.26% |
| 2013 FY | 136.57 Million CNY | 131.91% |
| 2013 Q4 | 136.57 Million CNY | 0.0% |
| 2013 Q2 | 64.35 Million CNY | -53.31% |
| 2013 Q1 | 137.83 Million CNY | 0.0% |
| 2012 FY | 58.89 Million CNY | 129.02% |
| 2011 FY | 25.71 Million CNY | 17.99% |
| 2010 FY | 21.79 Million CNY | -42.44% |
| 2009 FY | 37.86 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Beijing Scitop Bio-tech Co., Ltd. | -179.94 Million CNY | 235.012% |
| Lifecome Biochemistry Co.,Ltd. | 878.34 Million CNY | 72.34% |
| Chengdu Kanghua Biological Products Co., Ltd. | -844.61 Million CNY | 128.764% |
| NanHua Bio-medicine Co., Ltd | -449.53 Million CNY | 154.044% |
| Shandong Sito Bio-technology Co., Ltd. | 553.09 Million CNY | 56.075% |
| Zhejiang Wecome Pharmaceutical Company Limited | 105.08 Million CNY | -131.198% |
| Guangdong VTR Bio-Tech Co., Ltd. | -540.91 Million CNY | 144.914% |